NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Sutro Biopharma, Inc. (STRO) Stock Analysis

Sutro Biopharma, Inc. (STRO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

STRO

$20.07

−$0.47 (−2.29%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare STRO with… →

STRO Key Statistics

As of Sep 4, 2026
Trading
Open
$20.30
Previous Close
$20.54
Day's Range
19.86–20.43
52-Week Range
7.15–43.85
Volume
124.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.49
Valuation
Market Cap
$332.78M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
7.28
EPS (ttm)Profit attributable to each share over the last twelve months.
−17.37
Financials (FY)
Revenue (FY)
$102.48M+65.18%
Net Income (FY)
−$191.09M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
16.58M
1-Year Return
+96.76%
Dividend and dates
Avg Volume
329.20K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

STRO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+73.47%
2025−37.12%
2024−57.11%
2023−46.91%
2022−45.70%
2021−31.46%
2020+97.36%
2019+21.95%
2018 (partial year)−40.66%

As of September 4, 2026.

STRO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$102.48M−$191.09M−186.5%
2024$62.04M−$227.46M−366.6%
2023$153.73M−$106.79M−69.5%
2022$67.77M−$119.20M−175.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$102.48M—−$104.95M−$191.09M−186.5%
2024$62.04M—−$238.45M−$227.46M−366.6%
2023$153.73M—−$89.28M−$106.79M−69.5%
2022$67.77M—−$128.94M−$119.20M−175.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

STRO Valuation vs Biotechnology Median

Median of 656 stocks
MetricSTROBiotechnology medianvs median
P/S ratio7.2815.2652% below
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Sutro Biopharma, Inc. (STRO) carries a market capitalisation of $332.78M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 128 employees.

The most recent close on file for STRO is $20.07, dated September 4, 2026. That is −$0.47 (−2.29%) against the previous close. Over the past 52 weeks the price has ranged from $7.15 to $43.85. The latest close sits 180.7% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $102.48M. Against the prior fiscal year total of $62.04M, that is a change of +65.18%. The same year closed with a net loss of $191.09M. The reported profit margin is 0%. Trailing earnings per share are −17.37.

Across the 4 fiscal years on file, revenue moves from $67.77M in 2022 to $102.48M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 7.28. On price-to-sales that is 52.29% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +96.76%. Across 5 years the annualized return works out at −37.90%. Beta against the wider market is reported at 1.49. Annualized volatility over the trailing 7 years is 87.11%.

Growth & Income

No dividend is on file for STRO.

2026 is still running; the price is +73.47% year to date. The strongest complete calendar year on file is 2020 at +97.36%; the weakest is 2024 at −57.11%. Of the 7 complete calendar years on file, 2 finished higher.

Peer Comparison

Sutro Biopharma, Inc. (STRO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Sutro Biopharma, Inc. STRO $332.78M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Sutro Biopharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Sutro Biopharma, Inc.

Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Visit website →